View Financial HealthAll Cosmos Bio-Tech Holding 배당 및 자사주 매입배당 기준 점검 3/6All Cosmos Bio-Tech Holding 수익으로 충분히 충당되는 현재 수익률 3.33% 보유한 배당금 지급 회사입니다. 다음 지급일은 31st July, 2026 이며 배당락일은 다음과 같습니다. 8th July, 2026.핵심 정보3.3%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률-11.4%다음 배당 지급일31 Jul 26배당락일08 Jul 26주당 배당금n/a배당 성향46%최근 배당 및 자사주 매입 업데이트Upcoming Dividend • Jul 01Upcoming dividend of NT$1.00 per shareEligible shareholders must have bought the stock before 08 July 2026. Payment date: 31 July 2026. Payout ratio is a comfortable 46% and this is well supported by cash flows. Trailing yield: 3.3%. Lower than top quartile of Taiwanese dividend payers (4.9%). Higher than average of industry peers (1.2%).Upcoming Dividend • Aug 07Upcoming dividend of NT$0.50 per shareEligible shareholders must have bought the stock before 14 August 2025. Payment date: 05 September 2025. Payout ratio is a comfortable 28% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (2.8%).Upcoming Dividend • Jul 04Upcoming dividend of NT$1.00 per shareEligible shareholders must have bought the stock before 11 July 2024. Payment date: 01 August 2024. Payout ratio is a comfortable 50% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of Taiwanese dividend payers (4.2%). In line with average of industry peers (2.2%).Declared Dividend • May 15Dividend of NT$1.00 announcedShareholders will receive a dividend of NT$1.00. Ex-date: 11th July 2024 Payment date: 1st August 2024 Dividend yield will be 1.9%, which is lower than the industry average of 4.0%. Sustainability & Growth Dividend is well covered by both earnings (46% earnings payout ratio) and cash flows (8% cash payout ratio). The dividend has decreased over the past 66 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to decline by 49% to shift the payout ratio to a potentially unsustainable range, which is more than the 15% EPS decline seen over the last 5 years.Upcoming Dividend • Jul 03Upcoming dividend of NT$2.50 per share at 4.1% yieldEligible shareholders must have bought the stock before 10 July 2023. Payment date: 01 August 2023. Payout ratio is a comfortable 47% and this is well supported by cash flows. Trailing yield: 4.1%. Lower than top quartile of Taiwanese dividend payers (5.5%). Higher than average of industry peers (3.7%).공고 • Jun 23+ 1 more updateAll Cosmos Bio-Tech Holding Corporation Approves Cash Dividends for 2021All Cosmos Bio-Tech Holding Corporation announced that at the AGM held on June 22, 2022 approved Distributing cash dividends of TWD 96,051,002 by acknowledging the company's 2021 earnings distribution plan, based on the current number of 64,034,001 outstanding shares, TWD 1.50 per share.모든 업데이트 보기Recent updatesUpcoming Dividend • Jul 01Upcoming dividend of NT$1.00 per shareEligible shareholders must have bought the stock before 08 July 2026. Payment date: 31 July 2026. Payout ratio is a comfortable 46% and this is well supported by cash flows. Trailing yield: 3.3%. Lower than top quartile of Taiwanese dividend payers (4.9%). Higher than average of industry peers (1.2%).Reported Earnings • May 15First quarter 2026 earnings released: EPS: NT$0.078 (vs NT$0.19 in 1Q 2025)First quarter 2026 results: EPS: NT$0.078 (down from NT$0.19 in 1Q 2025). Revenue: NT$527.7m (down 3.7% from 1Q 2025). Net income: NT$5.27m (down 60% from 1Q 2025). Profit margin: 1.0% (down from 2.4% in 1Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.New Risk • Apr 05New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.3% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.9% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (NT$2.91b market cap, or US$90.9m).Reported Earnings • Mar 17Full year 2025 earnings released: EPS: NT$2.28 (vs NT$1.91 in FY 2024)Full year 2025 results: EPS: NT$2.28 (up from NT$1.91 in FY 2024). Revenue: NT$2.95b (up 20% from FY 2024). Net income: NT$153.0m (up 19% from FY 2024). Profit margin: 5.2% (in line with FY 2024). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.공고 • Mar 13All Cosmos Bio-Tech Holding Corporation, Annual General Meeting, Jun 16, 2026All Cosmos Bio-Tech Holding Corporation, Annual General Meeting, Jun 16, 2026. Location: 15 floor no,99, fu hsing n. rd., taipei city TaiwanReported Earnings • Nov 18Third quarter 2025 earnings released: EPS: NT$1.02 (vs NT$1.07 in 3Q 2024)Third quarter 2025 results: EPS: NT$1.02 (down from NT$1.07 in 3Q 2024). Revenue: NT$829.8m (up 11% from 3Q 2024). Net income: NT$68.8m (down 4.6% from 3Q 2024). Profit margin: 8.3% (down from 9.7% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 31Second quarter 2025 earnings released: EPS: NT$0.56 (vs NT$0.12 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.56 (up from NT$0.12 in 2Q 2024). Revenue: NT$739.5m (up 55% from 2Q 2024). Net income: NT$36.1m (up 353% from 2Q 2024). Profit margin: 4.9% (up from 1.7% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Aug 07Upcoming dividend of NT$0.50 per shareEligible shareholders must have bought the stock before 14 August 2025. Payment date: 05 September 2025. Payout ratio is a comfortable 28% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (2.8%).Reported Earnings • May 15First quarter 2025 earnings released: EPS: NT$0.20 (vs NT$0.45 in 1Q 2024)First quarter 2025 results: EPS: NT$0.20 (down from NT$0.45 in 1Q 2024). Revenue: NT$547.9m (up 4.7% from 1Q 2024). Net income: NT$13.1m (down 54% from 1Q 2024). Profit margin: 2.4% (down from 5.4% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.공고 • May 06All Cosmos Bio-Tech Holding Corporation to Report Q1, 2025 Results on May 13, 2025All Cosmos Bio-Tech Holding Corporation announced that they will report Q1, 2025 results on May 13, 2025Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to NT$33.45, the stock trades at a trailing P/E ratio of 16.7x. Average trailing P/E is 17x in the Chemicals industry in Taiwan. Total loss to shareholders of 57% over the past three years.Reported Earnings • Mar 26Full year 2024 earnings released: EPS: NT$2.01 (vs NT$2.18 in FY 2023)Full year 2024 results: EPS: NT$2.01 (down from NT$2.18 in FY 2023). Revenue: NT$2.46b (down 13% from FY 2023). Net income: NT$128.6m (down 7.7% from FY 2023). Profit margin: 5.2% (up from 4.9% in FY 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.공고 • Mar 14+ 1 more updateAll Cosmos Bio-Tech Holding Corporation, Annual General Meeting, Jun 16, 2025All Cosmos Bio-Tech Holding Corporation, Annual General Meeting, Jun 16, 2025. Location: 15 floor no,99, fu hsing n. rd., taipei city Taiwan공고 • Mar 06All Cosmos Bio-Tech Holding Corporation to Report Fiscal Year 2024 Results on Mar 13, 2025All Cosmos Bio-Tech Holding Corporation announced that they will report fiscal year 2024 results on Mar 13, 2025Reported Earnings • Nov 18Third quarter 2024 earnings released: EPS: NT$1.13 (vs NT$1.07 in 3Q 2023)Third quarter 2024 results: EPS: NT$1.13 (up from NT$1.07 in 3Q 2023). Revenue: NT$746.3m (up 8.4% from 3Q 2023). Net income: NT$72.1m (up 5.0% from 3Q 2023). Profit margin: 9.7% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.공고 • Nov 05All Cosmos Bio-Tech Holding Corporation to Report Q3, 2024 Results on Nov 12, 2024All Cosmos Bio-Tech Holding Corporation announced that they will report Q3, 2024 results on Nov 12, 2024Valuation Update With 7 Day Price Move • Oct 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$52.50, the stock trades at a trailing P/E ratio of 34.8x. Average forward P/E is 20x in the Chemicals industry in Taiwan. Total returns to shareholders of 52% over the past three years.Reported Earnings • Aug 31Second quarter 2024 earnings released: EPS: NT$0.12 (vs NT$0.61 in 2Q 2023)Second quarter 2024 results: EPS: NT$0.12 (down from NT$0.61 in 2Q 2023). Revenue: NT$478.4m (down 39% from 2Q 2023). Net income: NT$7.96m (down 80% from 2Q 2023). Profit margin: 1.7% (down from 4.9% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.공고 • Aug 20All Cosmos Bio-Tech Holding Corporation to Report Q2, 2024 Results on Aug 27, 2024All Cosmos Bio-Tech Holding Corporation announced that they will report Q2, 2024 results on Aug 27, 2024Upcoming Dividend • Jul 04Upcoming dividend of NT$1.00 per shareEligible shareholders must have bought the stock before 11 July 2024. Payment date: 01 August 2024. Payout ratio is a comfortable 50% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of Taiwanese dividend payers (4.2%). In line with average of industry peers (2.2%).Reported Earnings • May 19First quarter 2024 earnings released: EPS: NT$0.44 (vs NT$0.63 in 1Q 2023)First quarter 2024 results: EPS: NT$0.44 (down from NT$0.63 in 1Q 2023). Revenue: NT$523.5m (down 33% from 1Q 2023). Net income: NT$28.5m (down 29% from 1Q 2023). Profit margin: 5.4% (up from 5.2% in 1Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 14% per year, which means it is tracking significantly ahead of earnings growth.Declared Dividend • May 15Dividend of NT$1.00 announcedShareholders will receive a dividend of NT$1.00. Ex-date: 11th July 2024 Payment date: 1st August 2024 Dividend yield will be 1.9%, which is lower than the industry average of 4.0%. Sustainability & Growth Dividend is well covered by both earnings (46% earnings payout ratio) and cash flows (8% cash payout ratio). The dividend has decreased over the past 66 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to decline by 49% to shift the payout ratio to a potentially unsustainable range, which is more than the 15% EPS decline seen over the last 5 years.공고 • May 05All Cosmos Bio-Tech Holding Corporation to Report Q1, 2024 Results on May 13, 2024All Cosmos Bio-Tech Holding Corporation announced that they will report Q1, 2024 results on May 13, 2024New Risk • Apr 15New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.23b (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (4.9% net profit margin). Market cap is less than US$100m (NT$3.23b market cap, or US$99.8m).공고 • Mar 27All Cosmos Bio-Tech Holding Corporation, Annual General Meeting, Jun 21, 2024All Cosmos Bio-Tech Holding Corporation, Annual General Meeting, Jun 21, 2024.분석 기사 • Mar 22There May Be Reason For Hope In All Cosmos Bio-Tech Holding's (TWSE:4148) Disappointing EarningsSoft earnings didn't appear to concern All Cosmos Bio-Tech Holding Corporation's ( TWSE:4148 ) shareholders over the...Reported Earnings • Mar 19Full year 2023 earnings released: EPS: NT$2.18 (vs NT$5.75 in FY 2022)Full year 2023 results: EPS: NT$2.18 (down from NT$5.75 in FY 2022). Revenue: NT$2.83b (down 24% from FY 2022). Net income: NT$139.4m (down 62% from FY 2022). Profit margin: 4.9% (down from 9.9% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.공고 • Feb 01All Cosmos Bio-Tech Holding Corporation Announces the Retirement of Ling Siu Hung as Chief Operating OfficerAll Cosmos Bio-Tech Holding Corporation announced the retirement of Ling Siu Hung as Chief Operating Officer, effective January 31, 2024.Valuation Update With 7 Day Price Move • Dec 11Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$50.10, the stock trades at a trailing P/E ratio of 16.5x. Average trailing P/E is 21x in the Chemicals industry in Taiwan. Total returns to shareholders of 53% over the past three years.New Risk • Nov 30New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 32% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.2% net profit margin). Market cap is less than US$100m (NT$2.78b market cap, or US$88.8m).Reported Earnings • Nov 14Third quarter 2023 earnings released: EPS: NT$1.07 (vs NT$2.48 in 3Q 2022)Third quarter 2023 results: EPS: NT$1.07 (down from NT$2.48 in 3Q 2022). Revenue: NT$688.7m (down 45% from 3Q 2022). Net income: NT$68.7m (down 57% from 3Q 2022). Profit margin: 10.0% (down from 13% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.New Risk • Sep 10New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 20% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.Reported Earnings • Aug 26Second quarter 2023 earnings released: EPS: NT$0.61 (vs NT$1.47 in 2Q 2022)Second quarter 2023 results: EPS: NT$0.61 (down from NT$1.47 in 2Q 2022). Revenue: NT$786.5m (down 14% from 2Q 2022). Net income: NT$38.9m (down 59% from 2Q 2022). Profit margin: 4.9% (down from 10% in 2Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.New Risk • Aug 11New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.17b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (NT$3.17b market cap, or US$99.7m).Upcoming Dividend • Jul 03Upcoming dividend of NT$2.50 per share at 4.1% yieldEligible shareholders must have bought the stock before 10 July 2023. Payment date: 01 August 2023. Payout ratio is a comfortable 47% and this is well supported by cash flows. Trailing yield: 4.1%. Lower than top quartile of Taiwanese dividend payers (5.5%). Higher than average of industry peers (3.7%).Reported Earnings • Mar 28Full year 2022 earnings released: EPS: NT$5.75 (vs NT$3.09 in FY 2021)Full year 2022 results: EPS: NT$5.75 (up from NT$3.09 in FY 2021). Revenue: NT$3.70b (up 69% from FY 2021). Net income: NT$368.2m (up 86% from FY 2021). Profit margin: 9.9% (in line with FY 2021). Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has only increased by 44% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$66.00, the stock trades at a trailing P/E ratio of 10.5x. Average forward P/E is 16x in the Chemicals industry in Taiwan. Total returns to shareholders of 95% over the past three years.Reported Earnings • Nov 18Third quarter 2022 earnings released: EPS: NT$2.48 (vs NT$0.76 in 3Q 2021)Third quarter 2022 results: EPS: NT$2.48 (up from NT$0.76 in 3Q 2021). Revenue: NT$1.24b (up 127% from 3Q 2021). Net income: NT$158.7m (up 225% from 3Q 2021). Profit margin: 13% (up from 8.9% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to decline by 1.1% p.a. on average during the next 2 years, while revenues in the Chemicals industry in Taiwan are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non Independent Director Tau Lim was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Oct 13Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to NT$51.60, the stock trades at a trailing P/E ratio of 11.3x. Average forward P/E is 12x in the Chemicals industry in Taiwan. Total returns to shareholders of 36% over the past three years.Valuation Update With 7 Day Price Move • Sep 28Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to NT$55.70, the stock trades at a trailing P/E ratio of 12.2x. Average forward P/E is 13x in the Chemicals industry in Taiwan. Total returns to shareholders of 40% over the past three years.Reported Earnings • Sep 01Second quarter 2022 earnings released: EPS: NT$1.47 (vs NT$0.66 in 2Q 2021)Second quarter 2022 results: EPS: NT$1.47 (up from NT$0.66 in 2Q 2021). Revenue: NT$912.0m (up 61% from 2Q 2021). Net income: NT$94.3m (up 124% from 2Q 2021). Profit margin: 10% (up from 7.5% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.Board Change • Aug 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non Independent Director Tau Lim was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Jul 25Investor sentiment improved over the past weekAfter last week's 17% share price gain to NT$60.20, the stock trades at a trailing P/E ratio of 16.1x. Average forward P/E is 11x in the Chemicals industry in Taiwan. Total returns to shareholders of 19% over the past three years.Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improved over the past weekAfter last week's 23% share price gain to NT$54.40, the stock trades at a trailing P/E ratio of 14.5x. Average forward P/E is 11x in the Chemicals industry in Taiwan. Total returns to shareholders of 17% over the past three years.Board Change • Jul 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non Independent Director Tau Lim was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공고 • Jun 24+ 1 more updateAll Cosmos Bio-Tech Holding Corporation Announces Change in Remuneration CommitteeAll Cosmos Bio-Tech Holding Corporation announced change in Remuneration committee; Name of the previous position holder are Lo, Tze Wu; Yang, Yung Cheng; Lee, Wen Chuan. Name of the new position holder are Yang, Yung Cheng; Lee, Wen Chuan; Ho, Chia Fang. Resume of the new position holder: Yang, Yung Cheng Independent director of All Cosmos Bio-Tech Holding Corporation CPA, Moores Rowland CPAs. Lee, Wen Chuan Independent director of All Cosmos Bio-Tech Holding Corporation Head of Agricultural Technology Research Institute; Ho, Chia Fang Associate professor, Department of Law, SooChow University.공고 • Jun 23+ 1 more updateAll Cosmos Bio-Tech Holding Corporation Approves Cash Dividends for 2021All Cosmos Bio-Tech Holding Corporation announced that at the AGM held on June 22, 2022 approved Distributing cash dividends of TWD 96,051,002 by acknowledging the company's 2021 earnings distribution plan, based on the current number of 64,034,001 outstanding shares, TWD 1.50 per share.Upcoming Dividend • Jun 16Upcoming dividend of NT$1.50 per shareEligible shareholders must have bought the stock before 23 June 2022. Payment date: 20 July 2022. Payout ratio is a comfortable 40% but the company is not cash flow positive. Trailing yield: 2.8%. Lower than top quartile of Taiwanese dividend payers (6.0%). Lower than average of industry peers (6.8%).Reported Earnings • May 14First quarter 2022 earnings released: EPS: NT$1.07 (vs NT$0.42 in 1Q 2021)First quarter 2022 results: EPS: NT$1.07 (up from NT$0.42 in 1Q 2021). Revenue: NT$665.6m (up 62% from 1Q 2021). Net income: NT$68.5m (up 153% from 1Q 2021). Profit margin: 10% (up from 6.6% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • May 10Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to NT$68.20, the stock trades at a trailing P/E ratio of 22x. Average forward P/E is 12x in the Chemicals industry in Taiwan. Total returns to shareholders of 44% over the past three years.Price Target Changed • Apr 27Price target increased to NT$102Up from NT$68.00, the current price target is provided by 1 analyst. New target price is 34% above last closing price of NT$76.40. Stock is up 97% over the past year. The company posted earnings per share of NT$3.09 last year.Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 3 experienced directors. 5 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Wen Lee was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Apr 08Investor sentiment improved over the past weekAfter last week's 19% share price gain to NT$75.30, the stock trades at a trailing P/E ratio of 24.3x. Average forward P/E is 13x in the Chemicals industry in Taiwan. Total returns to shareholders of 49% over the past three years.Reported Earnings • Mar 30Full year 2021 earnings released: EPS: NT$3.09 (vs NT$1.28 in FY 2020)Full year 2021 results: EPS: NT$3.09 (up from NT$1.28 in FY 2020). Revenue: NT$2.20b (up 34% from FY 2020). Net income: NT$198.1m (up 141% from FY 2020). Profit margin: 9.0% (up from 5.0% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 22% compared to a 2.7% decline forecast for the industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improved over the past weekAfter last week's 23% share price gain to NT$64.20, the stock trades at a trailing P/E ratio of 26.8x. Average forward P/E is 11x in the Chemicals industry in Taiwan. Total returns to shareholders of 21% over the past three years.Valuation Update With 7 Day Price Move • Feb 24Investor sentiment improved over the past weekAfter last week's 16% share price gain to NT$48.50, the stock trades at a trailing P/E ratio of 20.2x. Average trailing P/E is 19x in the Chemicals industry in Taiwan. Total loss to shareholders of 14% over the past three years.Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS NT$0.76 (vs NT$0.54 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$548.7m (up 15% from 3Q 2020). Net income: NT$48.9m (up 42% from 3Q 2020). Profit margin: 8.9% (up from 7.3% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.Valuation Update With 7 Day Price Move • Oct 05Investor sentiment improved over the past weekAfter last week's 16% share price gain to NT$39.35, the stock trades at a trailing P/E ratio of 18.1x. Average forward P/E is 13x in the Chemicals industry in Taiwan. Total loss to shareholders of 37% over the past three years.Reported Earnings • Aug 31Second quarter 2021 earnings released: EPS NT$0.66 (vs NT$0.60 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: NT$565.5m (up 43% from 2Q 2020). Net income: NT$42.2m (up 9.2% from 2Q 2020). Profit margin: 7.5% (down from 9.7% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Jun 29Upcoming dividend of NT$1.00 per shareEligible shareholders must have bought the stock before 06 July 2021. Payment date: 30 July 2021. Trailing yield: 2.9%. Lower than top quartile of Taiwanese dividend payers (4.9%). In line with average of industry peers (2.8%).Reported Earnings • May 14First quarter 2021 earnings released: EPS NT$0.42 (vs NT$0.41 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: NT$409.9m (up 91% from 1Q 2020). Net income: NT$27.1m (up NT$53.3m from 1Q 2020). Profit margin: 6.6% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 36 percentage points per year, which is a significant difference in performance.공고 • May 12All Cosmos Bio-Tech Holding Corporation Announces Cash Dividend, Payable on July 30, 2021All Cosmos Bio-Tech Holding Corporation announced Cash dividend of NTD 64,034,001 with Ex-rights (ex-dividend) record date July 12,2021, and payment date of July 30, 2021.분석 기사 • Apr 20Is All Cosmos Bio-Tech Holding (TPE:4148) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Price Target Changed • Apr 20Price target decreased to NT$40.00Down from NT$98.50, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of NT$40.70. Stock is up 63% over the past year.공고 • Jan 22Acting for the Malaysian Subsidiary All Cosmos Bio-Tech Holding Corporation to Announce Temporary Shutdown of the Production DepartmentA foreign outsourcing employee from West Malaysia subsidiary All Cosmos Bio-Tech Holding Corporation is confirmed with Covid-19.To avoid the spread of the epidemic,the company decides to temporarily shutdown Production Department from 21st of January to 26th of January, and conduct disinfection and comprehensive inspection during the shutdown period. Employees tested with negative result can enter into factory to resume work.분석 기사 • Jan 10Returns On Capital At All Cosmos Bio-Tech Holding (TPE:4148) Paint An Interesting PictureWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...Is New 90 Day High Low • Jan 07New 90-day high: NT$39.40The company is up 9.0% from its price of NT$36.10 on 08 October 2020. The Taiwanese market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 15% over the same period.분석 기사 • Dec 22All Cosmos Bio-Tech Holding Corporation's (TPE:4148) Price Is Out Of Tune With EarningsWith a price-to-earnings (or "P/E") ratio of 50.6x All Cosmos Bio-Tech Holding Corporation ( TPE:4148 ) may be sending...분석 기사 • Dec 01Are Poor Financial Prospects Dragging Down All Cosmos Bio-Tech Holding Corporation (TPE:4148 Stock?With its stock down 9.7% over the past three months, it is easy to disregard All Cosmos Bio-Tech Holding (TPE:4148). To...Reported Earnings • Nov 13Third quarter 2020 earnings released: EPS NT$0.54The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$475.3m (up 4.9% from 3Q 2019). Net income: NT$34.5m (up 436% from 3Q 2019). Profit margin: 7.3% (up from 1.4% in 3Q 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 70% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Oct 29New 90-day low: NT$33.80The company is down 4.0% from its price of NT$35.10 on 30 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 6.0% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 4148 10년 미만 동안 배당금을 지급해 왔으며 이 기간 동안 지급액은 휘발성이었습니다.배당금 증가: 4148 8 년 동안만 배당금을 지급해 왔으며 그 이후 지급액이 감소했습니다.배당 수익률 vs 시장All Cosmos Bio-Tech Holding 배당 수익률 vs 시장4148의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (4148)3.3%시장 하위 25% (TW)1.5%시장 상위 25% (TW)5.1%업계 평균 (Chemicals)1.1%분석가 예측 (4148) (최대 3년)n/a주목할만한 배당금: 4148 의 배당금( 3.33% )은 TW 시장에서 배당금 지급자의 하위 25%( 1.45% )보다 높습니다.고배당: 4148 의 배당금( 3.33% )은 TW 시장에서 배당금 지급자의 상위 25%( 4.96% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 합리적으로 낮은 지불 비율 ( 46.3% )로 4148 의 배당금 지급은 수익으로 충분히 충당됩니다.주주 현금 배당현금 흐름 범위: 현금 지급 비율 ( 18.5% )이 낮기 때문에 4148 의 배당금 지급은 현금 흐름으로 잘 충당됩니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YTW 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/17 02:46종가2026/07/17 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스All Cosmos Bio-Tech Holding Corporation는 3명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Xuanyi YangCapital Securities CorporationHsiu Chi LinMasterlink Securities Investment AdvisoryYijun ChenSinoPac Securities Investment Service
Upcoming Dividend • Jul 01Upcoming dividend of NT$1.00 per shareEligible shareholders must have bought the stock before 08 July 2026. Payment date: 31 July 2026. Payout ratio is a comfortable 46% and this is well supported by cash flows. Trailing yield: 3.3%. Lower than top quartile of Taiwanese dividend payers (4.9%). Higher than average of industry peers (1.2%).
Upcoming Dividend • Aug 07Upcoming dividend of NT$0.50 per shareEligible shareholders must have bought the stock before 14 August 2025. Payment date: 05 September 2025. Payout ratio is a comfortable 28% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (2.8%).
Upcoming Dividend • Jul 04Upcoming dividend of NT$1.00 per shareEligible shareholders must have bought the stock before 11 July 2024. Payment date: 01 August 2024. Payout ratio is a comfortable 50% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of Taiwanese dividend payers (4.2%). In line with average of industry peers (2.2%).
Declared Dividend • May 15Dividend of NT$1.00 announcedShareholders will receive a dividend of NT$1.00. Ex-date: 11th July 2024 Payment date: 1st August 2024 Dividend yield will be 1.9%, which is lower than the industry average of 4.0%. Sustainability & Growth Dividend is well covered by both earnings (46% earnings payout ratio) and cash flows (8% cash payout ratio). The dividend has decreased over the past 66 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to decline by 49% to shift the payout ratio to a potentially unsustainable range, which is more than the 15% EPS decline seen over the last 5 years.
Upcoming Dividend • Jul 03Upcoming dividend of NT$2.50 per share at 4.1% yieldEligible shareholders must have bought the stock before 10 July 2023. Payment date: 01 August 2023. Payout ratio is a comfortable 47% and this is well supported by cash flows. Trailing yield: 4.1%. Lower than top quartile of Taiwanese dividend payers (5.5%). Higher than average of industry peers (3.7%).
공고 • Jun 23+ 1 more updateAll Cosmos Bio-Tech Holding Corporation Approves Cash Dividends for 2021All Cosmos Bio-Tech Holding Corporation announced that at the AGM held on June 22, 2022 approved Distributing cash dividends of TWD 96,051,002 by acknowledging the company's 2021 earnings distribution plan, based on the current number of 64,034,001 outstanding shares, TWD 1.50 per share.
Upcoming Dividend • Jul 01Upcoming dividend of NT$1.00 per shareEligible shareholders must have bought the stock before 08 July 2026. Payment date: 31 July 2026. Payout ratio is a comfortable 46% and this is well supported by cash flows. Trailing yield: 3.3%. Lower than top quartile of Taiwanese dividend payers (4.9%). Higher than average of industry peers (1.2%).
Reported Earnings • May 15First quarter 2026 earnings released: EPS: NT$0.078 (vs NT$0.19 in 1Q 2025)First quarter 2026 results: EPS: NT$0.078 (down from NT$0.19 in 1Q 2025). Revenue: NT$527.7m (down 3.7% from 1Q 2025). Net income: NT$5.27m (down 60% from 1Q 2025). Profit margin: 1.0% (down from 2.4% in 1Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
New Risk • Apr 05New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.3% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.9% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (NT$2.91b market cap, or US$90.9m).
Reported Earnings • Mar 17Full year 2025 earnings released: EPS: NT$2.28 (vs NT$1.91 in FY 2024)Full year 2025 results: EPS: NT$2.28 (up from NT$1.91 in FY 2024). Revenue: NT$2.95b (up 20% from FY 2024). Net income: NT$153.0m (up 19% from FY 2024). Profit margin: 5.2% (in line with FY 2024). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
공고 • Mar 13All Cosmos Bio-Tech Holding Corporation, Annual General Meeting, Jun 16, 2026All Cosmos Bio-Tech Holding Corporation, Annual General Meeting, Jun 16, 2026. Location: 15 floor no,99, fu hsing n. rd., taipei city Taiwan
Reported Earnings • Nov 18Third quarter 2025 earnings released: EPS: NT$1.02 (vs NT$1.07 in 3Q 2024)Third quarter 2025 results: EPS: NT$1.02 (down from NT$1.07 in 3Q 2024). Revenue: NT$829.8m (up 11% from 3Q 2024). Net income: NT$68.8m (down 4.6% from 3Q 2024). Profit margin: 8.3% (down from 9.7% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 31Second quarter 2025 earnings released: EPS: NT$0.56 (vs NT$0.12 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.56 (up from NT$0.12 in 2Q 2024). Revenue: NT$739.5m (up 55% from 2Q 2024). Net income: NT$36.1m (up 353% from 2Q 2024). Profit margin: 4.9% (up from 1.7% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Aug 07Upcoming dividend of NT$0.50 per shareEligible shareholders must have bought the stock before 14 August 2025. Payment date: 05 September 2025. Payout ratio is a comfortable 28% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (2.8%).
Reported Earnings • May 15First quarter 2025 earnings released: EPS: NT$0.20 (vs NT$0.45 in 1Q 2024)First quarter 2025 results: EPS: NT$0.20 (down from NT$0.45 in 1Q 2024). Revenue: NT$547.9m (up 4.7% from 1Q 2024). Net income: NT$13.1m (down 54% from 1Q 2024). Profit margin: 2.4% (down from 5.4% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
공고 • May 06All Cosmos Bio-Tech Holding Corporation to Report Q1, 2025 Results on May 13, 2025All Cosmos Bio-Tech Holding Corporation announced that they will report Q1, 2025 results on May 13, 2025
Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to NT$33.45, the stock trades at a trailing P/E ratio of 16.7x. Average trailing P/E is 17x in the Chemicals industry in Taiwan. Total loss to shareholders of 57% over the past three years.
Reported Earnings • Mar 26Full year 2024 earnings released: EPS: NT$2.01 (vs NT$2.18 in FY 2023)Full year 2024 results: EPS: NT$2.01 (down from NT$2.18 in FY 2023). Revenue: NT$2.46b (down 13% from FY 2023). Net income: NT$128.6m (down 7.7% from FY 2023). Profit margin: 5.2% (up from 4.9% in FY 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
공고 • Mar 14+ 1 more updateAll Cosmos Bio-Tech Holding Corporation, Annual General Meeting, Jun 16, 2025All Cosmos Bio-Tech Holding Corporation, Annual General Meeting, Jun 16, 2025. Location: 15 floor no,99, fu hsing n. rd., taipei city Taiwan
공고 • Mar 06All Cosmos Bio-Tech Holding Corporation to Report Fiscal Year 2024 Results on Mar 13, 2025All Cosmos Bio-Tech Holding Corporation announced that they will report fiscal year 2024 results on Mar 13, 2025
Reported Earnings • Nov 18Third quarter 2024 earnings released: EPS: NT$1.13 (vs NT$1.07 in 3Q 2023)Third quarter 2024 results: EPS: NT$1.13 (up from NT$1.07 in 3Q 2023). Revenue: NT$746.3m (up 8.4% from 3Q 2023). Net income: NT$72.1m (up 5.0% from 3Q 2023). Profit margin: 9.7% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
공고 • Nov 05All Cosmos Bio-Tech Holding Corporation to Report Q3, 2024 Results on Nov 12, 2024All Cosmos Bio-Tech Holding Corporation announced that they will report Q3, 2024 results on Nov 12, 2024
Valuation Update With 7 Day Price Move • Oct 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$52.50, the stock trades at a trailing P/E ratio of 34.8x. Average forward P/E is 20x in the Chemicals industry in Taiwan. Total returns to shareholders of 52% over the past three years.
Reported Earnings • Aug 31Second quarter 2024 earnings released: EPS: NT$0.12 (vs NT$0.61 in 2Q 2023)Second quarter 2024 results: EPS: NT$0.12 (down from NT$0.61 in 2Q 2023). Revenue: NT$478.4m (down 39% from 2Q 2023). Net income: NT$7.96m (down 80% from 2Q 2023). Profit margin: 1.7% (down from 4.9% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
공고 • Aug 20All Cosmos Bio-Tech Holding Corporation to Report Q2, 2024 Results on Aug 27, 2024All Cosmos Bio-Tech Holding Corporation announced that they will report Q2, 2024 results on Aug 27, 2024
Upcoming Dividend • Jul 04Upcoming dividend of NT$1.00 per shareEligible shareholders must have bought the stock before 11 July 2024. Payment date: 01 August 2024. Payout ratio is a comfortable 50% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of Taiwanese dividend payers (4.2%). In line with average of industry peers (2.2%).
Reported Earnings • May 19First quarter 2024 earnings released: EPS: NT$0.44 (vs NT$0.63 in 1Q 2023)First quarter 2024 results: EPS: NT$0.44 (down from NT$0.63 in 1Q 2023). Revenue: NT$523.5m (down 33% from 1Q 2023). Net income: NT$28.5m (down 29% from 1Q 2023). Profit margin: 5.4% (up from 5.2% in 1Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 14% per year, which means it is tracking significantly ahead of earnings growth.
Declared Dividend • May 15Dividend of NT$1.00 announcedShareholders will receive a dividend of NT$1.00. Ex-date: 11th July 2024 Payment date: 1st August 2024 Dividend yield will be 1.9%, which is lower than the industry average of 4.0%. Sustainability & Growth Dividend is well covered by both earnings (46% earnings payout ratio) and cash flows (8% cash payout ratio). The dividend has decreased over the past 66 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to decline by 49% to shift the payout ratio to a potentially unsustainable range, which is more than the 15% EPS decline seen over the last 5 years.
공고 • May 05All Cosmos Bio-Tech Holding Corporation to Report Q1, 2024 Results on May 13, 2024All Cosmos Bio-Tech Holding Corporation announced that they will report Q1, 2024 results on May 13, 2024
New Risk • Apr 15New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.23b (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (4.9% net profit margin). Market cap is less than US$100m (NT$3.23b market cap, or US$99.8m).
공고 • Mar 27All Cosmos Bio-Tech Holding Corporation, Annual General Meeting, Jun 21, 2024All Cosmos Bio-Tech Holding Corporation, Annual General Meeting, Jun 21, 2024.
분석 기사 • Mar 22There May Be Reason For Hope In All Cosmos Bio-Tech Holding's (TWSE:4148) Disappointing EarningsSoft earnings didn't appear to concern All Cosmos Bio-Tech Holding Corporation's ( TWSE:4148 ) shareholders over the...
Reported Earnings • Mar 19Full year 2023 earnings released: EPS: NT$2.18 (vs NT$5.75 in FY 2022)Full year 2023 results: EPS: NT$2.18 (down from NT$5.75 in FY 2022). Revenue: NT$2.83b (down 24% from FY 2022). Net income: NT$139.4m (down 62% from FY 2022). Profit margin: 4.9% (down from 9.9% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.
공고 • Feb 01All Cosmos Bio-Tech Holding Corporation Announces the Retirement of Ling Siu Hung as Chief Operating OfficerAll Cosmos Bio-Tech Holding Corporation announced the retirement of Ling Siu Hung as Chief Operating Officer, effective January 31, 2024.
Valuation Update With 7 Day Price Move • Dec 11Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$50.10, the stock trades at a trailing P/E ratio of 16.5x. Average trailing P/E is 21x in the Chemicals industry in Taiwan. Total returns to shareholders of 53% over the past three years.
New Risk • Nov 30New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 32% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.2% net profit margin). Market cap is less than US$100m (NT$2.78b market cap, or US$88.8m).
Reported Earnings • Nov 14Third quarter 2023 earnings released: EPS: NT$1.07 (vs NT$2.48 in 3Q 2022)Third quarter 2023 results: EPS: NT$1.07 (down from NT$2.48 in 3Q 2022). Revenue: NT$688.7m (down 45% from 3Q 2022). Net income: NT$68.7m (down 57% from 3Q 2022). Profit margin: 10.0% (down from 13% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
New Risk • Sep 10New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 20% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.
Reported Earnings • Aug 26Second quarter 2023 earnings released: EPS: NT$0.61 (vs NT$1.47 in 2Q 2022)Second quarter 2023 results: EPS: NT$0.61 (down from NT$1.47 in 2Q 2022). Revenue: NT$786.5m (down 14% from 2Q 2022). Net income: NT$38.9m (down 59% from 2Q 2022). Profit margin: 4.9% (down from 10% in 2Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
New Risk • Aug 11New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.17b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (NT$3.17b market cap, or US$99.7m).
Upcoming Dividend • Jul 03Upcoming dividend of NT$2.50 per share at 4.1% yieldEligible shareholders must have bought the stock before 10 July 2023. Payment date: 01 August 2023. Payout ratio is a comfortable 47% and this is well supported by cash flows. Trailing yield: 4.1%. Lower than top quartile of Taiwanese dividend payers (5.5%). Higher than average of industry peers (3.7%).
Reported Earnings • Mar 28Full year 2022 earnings released: EPS: NT$5.75 (vs NT$3.09 in FY 2021)Full year 2022 results: EPS: NT$5.75 (up from NT$3.09 in FY 2021). Revenue: NT$3.70b (up 69% from FY 2021). Net income: NT$368.2m (up 86% from FY 2021). Profit margin: 9.9% (in line with FY 2021). Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has only increased by 44% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$66.00, the stock trades at a trailing P/E ratio of 10.5x. Average forward P/E is 16x in the Chemicals industry in Taiwan. Total returns to shareholders of 95% over the past three years.
Reported Earnings • Nov 18Third quarter 2022 earnings released: EPS: NT$2.48 (vs NT$0.76 in 3Q 2021)Third quarter 2022 results: EPS: NT$2.48 (up from NT$0.76 in 3Q 2021). Revenue: NT$1.24b (up 127% from 3Q 2021). Net income: NT$158.7m (up 225% from 3Q 2021). Profit margin: 13% (up from 8.9% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to decline by 1.1% p.a. on average during the next 2 years, while revenues in the Chemicals industry in Taiwan are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non Independent Director Tau Lim was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Oct 13Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to NT$51.60, the stock trades at a trailing P/E ratio of 11.3x. Average forward P/E is 12x in the Chemicals industry in Taiwan. Total returns to shareholders of 36% over the past three years.
Valuation Update With 7 Day Price Move • Sep 28Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to NT$55.70, the stock trades at a trailing P/E ratio of 12.2x. Average forward P/E is 13x in the Chemicals industry in Taiwan. Total returns to shareholders of 40% over the past three years.
Reported Earnings • Sep 01Second quarter 2022 earnings released: EPS: NT$1.47 (vs NT$0.66 in 2Q 2021)Second quarter 2022 results: EPS: NT$1.47 (up from NT$0.66 in 2Q 2021). Revenue: NT$912.0m (up 61% from 2Q 2021). Net income: NT$94.3m (up 124% from 2Q 2021). Profit margin: 10% (up from 7.5% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.
Board Change • Aug 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non Independent Director Tau Lim was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Jul 25Investor sentiment improved over the past weekAfter last week's 17% share price gain to NT$60.20, the stock trades at a trailing P/E ratio of 16.1x. Average forward P/E is 11x in the Chemicals industry in Taiwan. Total returns to shareholders of 19% over the past three years.
Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improved over the past weekAfter last week's 23% share price gain to NT$54.40, the stock trades at a trailing P/E ratio of 14.5x. Average forward P/E is 11x in the Chemicals industry in Taiwan. Total returns to shareholders of 17% over the past three years.
Board Change • Jul 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non Independent Director Tau Lim was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공고 • Jun 24+ 1 more updateAll Cosmos Bio-Tech Holding Corporation Announces Change in Remuneration CommitteeAll Cosmos Bio-Tech Holding Corporation announced change in Remuneration committee; Name of the previous position holder are Lo, Tze Wu; Yang, Yung Cheng; Lee, Wen Chuan. Name of the new position holder are Yang, Yung Cheng; Lee, Wen Chuan; Ho, Chia Fang. Resume of the new position holder: Yang, Yung Cheng Independent director of All Cosmos Bio-Tech Holding Corporation CPA, Moores Rowland CPAs. Lee, Wen Chuan Independent director of All Cosmos Bio-Tech Holding Corporation Head of Agricultural Technology Research Institute; Ho, Chia Fang Associate professor, Department of Law, SooChow University.
공고 • Jun 23+ 1 more updateAll Cosmos Bio-Tech Holding Corporation Approves Cash Dividends for 2021All Cosmos Bio-Tech Holding Corporation announced that at the AGM held on June 22, 2022 approved Distributing cash dividends of TWD 96,051,002 by acknowledging the company's 2021 earnings distribution plan, based on the current number of 64,034,001 outstanding shares, TWD 1.50 per share.
Upcoming Dividend • Jun 16Upcoming dividend of NT$1.50 per shareEligible shareholders must have bought the stock before 23 June 2022. Payment date: 20 July 2022. Payout ratio is a comfortable 40% but the company is not cash flow positive. Trailing yield: 2.8%. Lower than top quartile of Taiwanese dividend payers (6.0%). Lower than average of industry peers (6.8%).
Reported Earnings • May 14First quarter 2022 earnings released: EPS: NT$1.07 (vs NT$0.42 in 1Q 2021)First quarter 2022 results: EPS: NT$1.07 (up from NT$0.42 in 1Q 2021). Revenue: NT$665.6m (up 62% from 1Q 2021). Net income: NT$68.5m (up 153% from 1Q 2021). Profit margin: 10% (up from 6.6% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • May 10Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to NT$68.20, the stock trades at a trailing P/E ratio of 22x. Average forward P/E is 12x in the Chemicals industry in Taiwan. Total returns to shareholders of 44% over the past three years.
Price Target Changed • Apr 27Price target increased to NT$102Up from NT$68.00, the current price target is provided by 1 analyst. New target price is 34% above last closing price of NT$76.40. Stock is up 97% over the past year. The company posted earnings per share of NT$3.09 last year.
Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 3 experienced directors. 5 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Wen Lee was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Apr 08Investor sentiment improved over the past weekAfter last week's 19% share price gain to NT$75.30, the stock trades at a trailing P/E ratio of 24.3x. Average forward P/E is 13x in the Chemicals industry in Taiwan. Total returns to shareholders of 49% over the past three years.
Reported Earnings • Mar 30Full year 2021 earnings released: EPS: NT$3.09 (vs NT$1.28 in FY 2020)Full year 2021 results: EPS: NT$3.09 (up from NT$1.28 in FY 2020). Revenue: NT$2.20b (up 34% from FY 2020). Net income: NT$198.1m (up 141% from FY 2020). Profit margin: 9.0% (up from 5.0% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 22% compared to a 2.7% decline forecast for the industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improved over the past weekAfter last week's 23% share price gain to NT$64.20, the stock trades at a trailing P/E ratio of 26.8x. Average forward P/E is 11x in the Chemicals industry in Taiwan. Total returns to shareholders of 21% over the past three years.
Valuation Update With 7 Day Price Move • Feb 24Investor sentiment improved over the past weekAfter last week's 16% share price gain to NT$48.50, the stock trades at a trailing P/E ratio of 20.2x. Average trailing P/E is 19x in the Chemicals industry in Taiwan. Total loss to shareholders of 14% over the past three years.
Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS NT$0.76 (vs NT$0.54 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$548.7m (up 15% from 3Q 2020). Net income: NT$48.9m (up 42% from 3Q 2020). Profit margin: 8.9% (up from 7.3% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
Valuation Update With 7 Day Price Move • Oct 05Investor sentiment improved over the past weekAfter last week's 16% share price gain to NT$39.35, the stock trades at a trailing P/E ratio of 18.1x. Average forward P/E is 13x in the Chemicals industry in Taiwan. Total loss to shareholders of 37% over the past three years.
Reported Earnings • Aug 31Second quarter 2021 earnings released: EPS NT$0.66 (vs NT$0.60 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: NT$565.5m (up 43% from 2Q 2020). Net income: NT$42.2m (up 9.2% from 2Q 2020). Profit margin: 7.5% (down from 9.7% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Jun 29Upcoming dividend of NT$1.00 per shareEligible shareholders must have bought the stock before 06 July 2021. Payment date: 30 July 2021. Trailing yield: 2.9%. Lower than top quartile of Taiwanese dividend payers (4.9%). In line with average of industry peers (2.8%).
Reported Earnings • May 14First quarter 2021 earnings released: EPS NT$0.42 (vs NT$0.41 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: NT$409.9m (up 91% from 1Q 2020). Net income: NT$27.1m (up NT$53.3m from 1Q 2020). Profit margin: 6.6% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 36 percentage points per year, which is a significant difference in performance.
공고 • May 12All Cosmos Bio-Tech Holding Corporation Announces Cash Dividend, Payable on July 30, 2021All Cosmos Bio-Tech Holding Corporation announced Cash dividend of NTD 64,034,001 with Ex-rights (ex-dividend) record date July 12,2021, and payment date of July 30, 2021.
분석 기사 • Apr 20Is All Cosmos Bio-Tech Holding (TPE:4148) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Price Target Changed • Apr 20Price target decreased to NT$40.00Down from NT$98.50, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of NT$40.70. Stock is up 63% over the past year.
공고 • Jan 22Acting for the Malaysian Subsidiary All Cosmos Bio-Tech Holding Corporation to Announce Temporary Shutdown of the Production DepartmentA foreign outsourcing employee from West Malaysia subsidiary All Cosmos Bio-Tech Holding Corporation is confirmed with Covid-19.To avoid the spread of the epidemic,the company decides to temporarily shutdown Production Department from 21st of January to 26th of January, and conduct disinfection and comprehensive inspection during the shutdown period. Employees tested with negative result can enter into factory to resume work.
분석 기사 • Jan 10Returns On Capital At All Cosmos Bio-Tech Holding (TPE:4148) Paint An Interesting PictureWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...
Is New 90 Day High Low • Jan 07New 90-day high: NT$39.40The company is up 9.0% from its price of NT$36.10 on 08 October 2020. The Taiwanese market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 15% over the same period.
분석 기사 • Dec 22All Cosmos Bio-Tech Holding Corporation's (TPE:4148) Price Is Out Of Tune With EarningsWith a price-to-earnings (or "P/E") ratio of 50.6x All Cosmos Bio-Tech Holding Corporation ( TPE:4148 ) may be sending...
분석 기사 • Dec 01Are Poor Financial Prospects Dragging Down All Cosmos Bio-Tech Holding Corporation (TPE:4148 Stock?With its stock down 9.7% over the past three months, it is easy to disregard All Cosmos Bio-Tech Holding (TPE:4148). To...
Reported Earnings • Nov 13Third quarter 2020 earnings released: EPS NT$0.54The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$475.3m (up 4.9% from 3Q 2019). Net income: NT$34.5m (up 436% from 3Q 2019). Profit margin: 7.3% (up from 1.4% in 3Q 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 70% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Oct 29New 90-day low: NT$33.80The company is down 4.0% from its price of NT$35.10 on 30 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 6.0% over the same period.